REFERENCES
- Rice LB. Antimicrobial resistance in gram-positive bacte-ria. Am J Med 2006; 34 ((5, Suppl 1) 511-519.
- MacGowan AP. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008; 62 Suppl 2(ii 105-114.
- NNIS. National Nosocomial Infections Surveillance (NNIS) Systems Report. 2004. Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32, 8: 470-485.
- Tenover FC, McDougal LK, Goering RV, Killgore G, Projan SJ, Patel JB et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006; 44 (1): 108-118.
- Willems RJ, Top J, van Santen M, Robinson DA, Coque TM, Baquero F, et al. Global spread of vancomycin-resistant En-terococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11 (6): 821–828.
- Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence and spread of van-comycin resistance among enterococci in Europe. Euro Surveill 2008; 13 (47).
- Eliopoulos GM. Antimicrobial agents for treatment of seri-ous infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis 2005; 24 (12): 826–831.
- Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of com-plicated skin and skin-structure infections. Clin Infect Dis 2004; 38 (12): 1673–1681.
- Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karch-mer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus au-reus. N Engl J Med 2006; 355 (7): 653–665.
- EUCAST. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST Technical Note on daptomycin. Clin Microbiol Infect 2006; 12 (6): 599–601.
- Levine DP. Clinical experience with daptomycin: bacter-aemia and endocarditis. J Antimicrob Chemother 2008; 62 Suppl 3(iii 35-39.
- Seaton RA. Daptomycin: rationale and role in the man-agement of skin and soft tissue infections. J Antimicrob Chemother 2008; 62 Suppl 3(iii15-23).
- Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicro-bial activity of daptomycin against multidrug-resistant Gram-pos-itive strains collected worldwide. Diagn Microbiol Infect Dis 2004; 50 (3): 201–204.
- Hawkey PM. Pre-clinical experience with daptomycin. Journal of Antimicrobial Chemotherapy 2008; 62 Suppl 3 (iii7-14).
- Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicro-bial susceptibility of Gram-positive bacteria isolated from Euro-pean medical centres: Results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006; 12 (9): 844–852.
- Clinical and Laboratory Standards Institute. M7-A7, Meth-ods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. Wayne, PA: CLSI, 2006.
- Clinical and Laboratory Standards Institute. M100-518, Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Wayne, PA: CLSI. 2008;
- Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Mi-crobiol Infect 2008; 14 Suppl 6 (2-8.